19 Dec 2019 09:52 ET
09:52 AM EST, 12/19/2019 (MT Newswires) -- Theratechnologies (TH.TO) fell 3.3% to a 52-week low after the company on Thursday said it expects 2019 revenue will rise 40% from the prior year, well below market expectations. The pharmaceutical company, which concentrates on HIV treatments, said 2019 revenue should be near US$63.3 million, with fourth-quarter sales pegged at US$16.5 million, 18% above the year-prior quarter. Capital IQ's consensus forecast for the company's 2019 revenue was US$87.32 million, while fourth-quarter sales were estimated to be US$25.3 million. For 2020, Theratechnologies said it expects revenue of US$83 million to US$87 million, with cash flow sufficient to fund operations and research. |